Is Azenta (AZTA) Undervalued Following Its CEO Change?

Leadership change sets the stage for a closer look at Azenta stock

Azenta (AZTA) is in the spotlight after Chief Executive Officer John Marotta resigned on August 22, 2026, and board member Dr. Martin Madaus stepped in as interim CEO and president.

This leadership shift, combined with the recent full repayment of a US$35 million vendor loan linked to the B Medical Systems sale, provides fresh context for assessing how Azenta stock fits in a portfolio.

Over the past year, Azenta’s share price has been choppy, with a 90 day share price return of 38.08% contrasting with a year to date share price return that is down 6.17%. The 1 year total shareholder return of 3.40% sits against a 3 year total shareholder return that has declined 39.95%, suggesting recent momentum has picked up even as longer term holders remain under pressure.

Spot fresh leadership shifts like Azenta’s and compare them with other life science and healthcare stocks by scanning our hand picked 37 healthcare AI stocks.

Azenta runs a specialised life sciences platform, yet the stock has a mixed return record and a sharp 90 day rebound. The next step is to see whether that business quality is already fully reflected in today’s price.

Most Popular Narrative: 11.1% Undervalued

The most followed Azenta narrative points to a fair value of $35.25 per share compared with the last close at $31.33. That gap hinges on how future earnings and margins play out over the next few years.

The ongoing trend of life sciences digitization and automation is reflected in Azenta's improved operational execution and introduction of more automated solutions. These efficiency gains, alongside investments in R&D and product management, are producing significant gross margin and EBITDA margin expansion, pointing to further net margin improvements with scale.

Read the complete narrative.

Want to see the earnings path that sits behind that higher fair value for Azenta? The narrative leans heavily on margin repair, steadier revenue growth, and a richer future earnings multiple.

Result: Fair Value of $35.25 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to factor in risks to the Azenta story, including delayed orders for higher margin equipment and softer demand in Gene Synthesis and Sanger Sequencing.

Find out about the key risks to this Azenta narrative.

Another view on Azenta’s valuation

The Azenta narrative leans on a fair value of $35.25 per share, yet the SWS DCF model tells a different story. On that approach, the estimated future cash flow value is $22.50, so at a share price of $31.33 the stock screens as overvalued instead of undervalued. Which lens do you trust more when cash generation and earnings are pointing in different directions?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Azenta for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment this mixed around Azenta, it makes sense to review the numbers yourself and move quickly to shape your own view with the 2 key rewards.

Looking for more investment ideas beyond Azenta?

If Azenta has sharpened your focus, do not stop here. Broaden your watchlist with fresh ideas that match different goals, risk levels, and income needs.

• Target potential mispricing by scanning a curated 47 high quality undervalued stocks that may offer stronger fundamentals than the price suggests.
• Strengthen your portfolio’s foundation by reviewing a list of solid balance sheet and fundamentals (52 results) that could handle tougher conditions without stressing your capital.
• Grow your income stream by checking out a hand picked 11 dividend fortresses that focuses on higher yielding opportunities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com